

GENETICS, BIOINFORMATICS, AND SYSTEMS BIOLOGY COLLOQUIUM

**THURSDAY OCTOBER 27
12:00 PM PST**

@ LEICHTAG AUDITORIUM RM 107

ZOOM INFO:

LINK: [HTTPS://UCHEALTH.ZOOM.US/J/84129605652?](https://uchealth.zoom.us/j/84129605652?pwd=KOMYSMNIKZQZYXGVTERCDDJRNG9QDZ09)
[PWD=KOMYSMNIKZQZYXGVTERCDDJRNG9QDZ09](https://uchealth.zoom.us/j/84129605652?pwd=KOMYSMNIKZQZYXGVTERCDDJRNG9QDZ09)

PASSWORD: GENOME

CLICK:



HOLLY B. KORDASIEWICZ, PHD

*VICE PRESIDENT, NEUROLOGY RESEARCH
IONIS PHARMACEUTICALS*

ANTISENSE OLIGONUCLEOTIDES (ASOs) FOR THE TREATMENT OF NEUROLOGICAL DISEASES

Antisense oligonucleotides (ASOs) have emerged as a viable therapeutic modality for treating previously intractable diseases of the central nervous system (CNS). RNA therapeutics, like ASOs, can target often undruggable, genetically validated, disease modifying targets. ASOs delivered to the cerebral spinal fluid modulate their target RNAs throughout the CNS. The advancements, opportunities, challenges, and lessons learned in the development of ASOs for the treatment of neurological diseases will be discussed.

LUNCH SPONSORED BY: illumina®

**PRESENTED
BY:**



GENOMIC.WEBLY.COM

For information on
upcoming lectures,
Visit:
genomic.weebly.com

